Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
At 4 years, there was no significant difference in overall survival.
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
A retrospective study demonstrates that TKI therapy discontinuation occurs frequently and successfully both in clinical trials and in the general population.
Researchers sought to determine whether JAK1 inhibition would be a therapeutic target in patients with AF10-rearranged acute myeloid leukemia.
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Researchers sought to determine what genetic mutations may have prognostic significance for chemotherapy and stem cell transplant in patients with AML.
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
The 12-month overall survival rate was 88%.
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Researchers sought to determine whether epigenetic mutations may affect AML outcomes in elderly patients, and how that can inform use of decitabine-based regimens.
Outcomes have improved during the past decade for patients with acute lymphoblastic leukemia who undergo haploidentical hematopoietic cell transplantation.
The IDEAL trial found that adolescents and young adults with B-cell acute lymphoblastic leukemia may benefit from restrictive diets and increased exercise.
Researchers sought to determine the long-term safety and efficacy of KTE-X19 in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Researchers sought to determine whether using azacitidine would be safe for infants with ALL with a KMT2A rearrangement.
Risk particularly high for acute myeloid leukemia before age 5 years.
Researchers sought to determine what characteristics may drive physician decisions to give immunoglobulin supplementation for patients with B-cell ALL.
Researchers sought to determine whether combination platelet and blast counts would be a helpful predictive model for pediatric patients with ALL.
Researchers sought to determine whether NR3C1 mutations might influence glucocorticoid resistance and treatment outcomes in pediatric patients with ALL.
Researchers sought to determine whether quizartinib-based combination therapies would be safe and effective treatment options for patients with AML.
Investigators analyzed the association between hepatic SOS and short-term application of 6-TG in 3983 pediatric ALL patients.
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Reduction in fat gain not seen in overall cohort, but stratified analysis showed benefit among those overweight, obese at baseline.
Researchers sought to determine whether whole-genome sequencing may be a better risk stratification tool compared with conventional cytogenetic analysis.
Researchers sought to determine whether a lower dose of anthracycline would have the same efficacy and better safety as standard dosage in patients with APL.
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Researchers investigated whether there may be a trend of patients with AML developing symptoms of PTSD.
Researchers sought to determine whether high cortactin and HS1 expression may be linked with poorer prognosis for patients with B-ALL.
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
Researchers sought to determine whether MRD status could be a helpful prognostic tool for survival in patients with acute leukemia prior to allo-HSCT.
A case study with a literature review demonstrates potential antiviral effect of TKI therapy in patients with cancer and COVID-19.
Researchers sought to determine the incidence and risk factors for acute kidney in patients with AML who are undergoing induction chemotherapy.